PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
Competition between direct oral anticoagulants (DOACs) is heating up. All four DOACs sold in Japan are indicated for the prevention of stroke associated with non-valvular atrial fibrillation (AF), while three are also approved for the treatment and prevention of relapse…
To read the full story
Related Article
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
August 26, 2016
- Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
August 25, 2016
BUSINESS
- JB Banks on Sustained Aid to Double Plasma Processing Capacity
October 27, 2026
- Keytruda Tops Japan Drug Sales in April-September: Encise
October 27, 2026
- Japan Pharma Earnings Season Opens as Drug Price Cuts, Patent Cliffs Test Growth
October 27, 2026
- Takeda Opens New Kyoto Garden Area to Preserve Plants Used in Cultural Heritage
October 27, 2026
- Otsuka Ramps Up CVC Investments, Already Backs 2 Biotechs
October 27, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…